十一月 2025
- Home
- RECORDATI
十一月 2025的RECORDATI市场份额分析
Chemicals Business We manufacture and provide our Active Pharmaceutical Ingredient (API) portfolio to customers worldwide. Recordati has a long-standing track record within its chemical division, with strong internal capabilities, internationally recognised quality products and long-term relationships with our customers. Our Active Principles cover several therapeutic areas in both primary and specialty care, meeting the… Continue reading Our Business – Chemicals Business
RECORDATI(包含公司地区分支机构)
查看更多网站流量和参与度信息- recordati.it
RECORDATI收入截至 十一月 2025为 > 1B
RECORDATI主要域名产生的收入
3 年中RECORDATI主要域名的收入
RECORDATI主要域名的收入
十一月 2025的RECORDATI股票价格
RECORDATI的股票交易代码为 REC。您可以在下面查看过去 12 个月的RECORDATI股票表现(最多 十一月 2025)
RECORDATI热门域名的总访问量
了解RECORDATI市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
RECORDATI热门域名的平均访问时长
分析RECORDATI参与度指标。
过去 3 个月的平均访问时长
子公司明细
RECORDATI热门域名的平均页面浏览量
了解RECORDATI如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
RECORDATI 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Recordati S.p.A. acquired EUSA Pharma Ltd for $824M on Mar 1st '22.In March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.28 million.
六月 11, 2023阅读更多
新闻Astrazeneca partnered with Recordati S.p.A. on May 1st '17.AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, headquartered in the U.K., announced that it has partnered up with Recordati, an Italy-based pharmaceutical company in May 2017.
十一月 3, 2020阅读更多
新闻Recordati S.p.A. partners with Novelion Therapeutics Inc..In February, Recordati signed a license agreement with Aegerion Pharmaceuticals Inc. for the exclusive rights to commercialize Juxtapid®, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan.
七月 30, 2019阅读更多
查看 RECORDATI 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。